Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Change in Receivables (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Change in Receivables for 4 consecutive years, with $1.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Receivables rose 275.99% year-over-year to $1.9 million, compared with a TTM value of $578000.0 through Sep 2025, down 50.68%, and an annual FY2024 reading of -$32.6 million, down 433.72% over the prior year.
  • Change in Receivables was $1.9 million for Q3 2025 at Atara Biotherapeutics, up from -$8.9 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $40.0 million in Q4 2022 and bottomed at -$39.8 million in Q1 2023.
  • Average Change in Receivables over 4 years is $61800.0, with a median of -$31000.0 recorded in 2022.
  • The sharpest move saw Change in Receivables soared 454.84% in 2023, then crashed 30474.55% in 2024.
  • Year by year, Change in Receivables stood at $40.0 million in 2022, then fell by 15.08% to $33.9 million in 2023, then crashed by 99.57% to $147000.0 in 2024, then soared by 1201.36% to $1.9 million in 2025.
  • Business Quant data shows Change in Receivables for ATRA at $1.9 million in Q3 2025, -$8.9 million in Q2 2025, and $7.4 million in Q1 2025.